Giant Cell Arteritis Global Clinical Trials Review, H2, 2017

2017-08-30
Price :
Published : Aug-2017
No. of Pages : 45

Giant Cell Arteritis Global Clinical Trials Review, H2, 2017

Summary

GlobalData’s clinical trial report, “Giant Cell Arteritis Global Clinical Trials Review, H2, 2017” provides an overview of Giant Cell Arteritis clinical trials scenario. This report provides top line data relating to the clinical trials on Giant Cell Arteritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Radiation Dose Management Market by Products & Services (Standalone Solutions, Integrated Solutions, Services), Modality (Computed Tomography, Nuclear Medicine), Application (Oncology, Cardiology, Orthopedic), End User (Hospitals) – Global Forecast to 2025

“Radiation dose management market is projected to grow at CAGR of 13.9% from 2020 to 2025” The global radiation dose management market is projected to reach USD 422.65 million by 2025 from USD 220.22 million in 2020, at a CAGR of 13.9% from 2020 to 2025. Growth in this market is driven by the increasing use of medical imaging modalities due to the rising incidence of chronic diseases, increasing concerns over radiation dose exposure, growth in the installed base of radiology equipment, and growing awareness on radiation dose management. On the other hand, the lack of standardized procedures and dose protocols for radiation dose management for healthcare organizations is a major market challenge. “Radiation dose management solutions segment to witness the highest growth during t......
$4950

Taiwan Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Taiwan Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report, "Taiwan Healthcare, Regulatory and Reimbursement Landscape - CountryFocus". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in the Taiwan. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of the Taiwan. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house an......
$1995

Coronavirus Disease 2019 (COVID-19) – Epidemiology Analysis and Forecast (July 2020 Edition)

Coronavirus Disease 2019 (COVID-19) - Epidemiology Analysis and Forecast (July 2020 Edition) Summary Globally, the total confirmed cases of COVID-19 have reached over 17 million with over 667,000 deaths and 9,964,000 recoveries. The US continues to be the most affected country globally, with over 4.4 million cases. The US fell to ranking seventh globally in terms of per capita daily incident rates, however, the US is still ranked number one in terms of total daily incidence. South Africa reported over 7,200 new confirmed cases of COVID-19 yesterday and over 7,000 new confirmed cases of COVID-19 on Tuesday. These are the two lowest daily incident rates reported by South Africa since the beginning of July, however, South Africa still remains as ranking fourth in total daily incident rat......
$1995

Opioid Use Disorder – Opportunity Analysis and Forecasts to 2028

Opioid Use Disorder - Opportunity Analysis and Forecasts to 2028 Summary Opioids are synthetic or natural agents that stimulate opioid receptors in the brain and nervous system. Opioids are often used to treat patients suffering from pain. When taken in the prescribed quantities, opioids do not generally lead to addiction. Opioid use disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs, and prolonged self-administration of opioid drugs. As the brain adapts to a prolonged opioid use, the patient's tolerance increases, so a higher dose of opioid is needed to stimulate the mesolimbic system in the same way as the original dose, leading patients to use continued higher doses of the drug. There are two......
$10995

Opioid Use Disorder – Epidemiology Forecast to 2028

Opioid Use Disorder - Epidemiology Forecast to 2028 Summary Opioid use disorder (OUD) is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as a problematic pattern of opioid use leading to clinically significant impairment or distress. Symptoms of OUD include strong desire for opioids, inability to control or reduce use, continued use despite interference in major obligations or social functioning, use of larger amounts over time, development of tolerance, spending a great deal of time to obtain and use opioids, and withdrawal symptoms that occur after stopping or reducing use such as negative mood, nausea or vomiting, muscle aches, diarrhea, fever, and insomnia (American Psychiatric Association, 2013). GlobalData epidemiologists utilized histor......
$3995

Coronavirus Disease 2019 (COVID-19) – Pipeline and Clinical Trial Analysis – June 2020

Coronavirus Disease 2019 (COVID-19) - Pipeline and Clinical Trial Analysis - June 2020 Summary The biopharmaceutical industry has risen to meet the challenge posed by this novel virus: hundreds of companies across the globe have entered the race to develop a treatment and a preventive vaccine. While the industry has shown its mettle by immediately initiating research on agents for COVID-19, the progress of R&D in general has been adversely impacted, with delays in clinical trial timelines and regulatory decisions across disease areas. Over the coming months, as trial data readouts become available, frontrunners will emerge in both the therapeutic and preventive categories. Currently, the therapeutics space is dominated by candidates already approved for other disease indications; one of......
$2495

Coronavirus Disease 2019 (COVID-19) – Analysis of the Emerging Disease Landscape – June 2020

Coronavirus Disease 2019 (COVID-19) - Analysis of the Emerging Disease Landscape - June 2020 Summary The Epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space. The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions. A range of players - from pharma and biotech firms to academic institutions and government agencies - have thrown their hats in the ring. Scope - Global epidemiology metrics and trends - Snapshot of epidemiological trends to date in the top three most-affected countries - An overview of the pipeline for antivirals and vaccines - Summary of available efficacy data - An assessment of the clinical trials landscape by phase, sponsor ......
$2495

Contract Manufacturing Service Agreements – Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion

Contract Manufacturing Service Agreements - Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion Summary This report is a brand new publication covering contract service agreements, across a range of different services and manufacturing scales. The number of contract service agreements secured serves as a primary indicator of a CMO's performance. Contract Manufacturing Service Agreements is critical for establishing an understanding of the overall CMO industry, the range of services provided and the features of some of the largest CMOs participating in the industry. This report gives an important expert quantitative analysis on the contract manufacturing industry. Findings are based on the industry's most comprehensive databases of the CMO industry (GlobalData'......
$4995

COVID-19 Pipeline of Small and Mid-Cap Bio/Pharma Companies – Coronavirus Disease 2019 Sector Forecast

COVID-19 Pipeline of Small and Mid-Cap Bio/Pharma Companies - Coronavirus Disease 2019 Sector Forecast Summary The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact Small and Mid Bio/Pharma Companies. Scope - This PowerPoint based report gives an important expert analysis on how the developement of vaccines and therapeutics for COVID-19 has been approached by Small and Mid Cap Bio/Pharma Companies. - Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis. Reasons to Buy - An overview of how Small and Mid Cap Bio/Pharma Companies have approached the developemnt of vaccines and therapeutics for the COVID-19 pandemic.......
$695

COVID-19 Impact on Inovio Pharmaceuticals Inc.

COVID-19 Impact on Inovio Pharmaceuticals Inc. Summary This PowerPoint based report gives an important expert analysis on how COVID-19 will affect Inovio Pharmaceuticals Inc. Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis. Scope - The coronavirus (COVID-19) company impact report analyses how the pandemic will impact Inovio Pharmaceuticals Inc. performance. Inovio's focus is on DNA-based vaccines requiring a novel route of administration - Inovio's pipeline is most active in early-stage drug development - INO-4800 is Inovio's COVID-19 vaccine - Funding from different sources for INO-4800 Reasons to Buy - An overview of how Inovio Pharmaceuticals Inc. will......
$495
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy